New drug combo shrinks prostate tumors before radiation
NCT ID NCT02160353
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug combination (abiraterone acetate plus prednisolone and hormone therapy) given before radiation in 45 men with high-risk localized prostate cancer. The goal was to see if the treatment could shrink tumors and lower PSA levels. The approach aims to improve cancer control before definitive radiotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH RISK LOCALISED PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cork University Hospital
Cork, Ireland
-
St Luke's Hospital
Dublin, 6, Ireland
-
University Hospital Galway
Galway, Ireland
More trials for these conditions
Other studies related to the condition(s) this trial covers.